Fre full-text Reference

Title Average Ratingsort ascending
Psychodynamic psychotherapy, therapeutic touch and cancer. A review of the method of intervention and studv of 75 cases 100.00%
The Wisdom of Crowds 100.00%
Democracy 2.1 How to Make a Bunch of Lazy and Selfish People Work Together? A handbook about collective Intelligence in Politics 100.00%
Psorinum therapy in treating stomach, gall bladder, pancreatic, and liver cancers: a prospective clinical study. 100.00%
Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate c 100.00%
Ukrain - a new cancer cure? A systematic review of randomised clinical trials. 90.00%
The PEP-C regimen for recurring/refractory lymphoma: low-dose metronomic, multidrug therapy. 90.00%
Vitamin D binding protein-macrophage activating factor directly inhibits proliferation, migration, and uPAR expression of prosta 90.00%
Pomegranate juice does not impair clearance of oral or intravenous midazolam, a probe for cytochrome P450-3A activity........... 90.00%
Randomized Trials of Selenium, Vitamin E, or Vitamin C for Prostate Cancer Prevention 90.00%
Tumor therapy with Amanita phalloides (death cap): stabilization of B-cell chronic lymphatic leukemia. 90.00%
WHO’S AFRAID OF A CURE FOR CANCER? - The struggle for an alternative cancer drug 90.00%
Why are tumour blood vessels abnormal and why is it important to know? 90.00%
Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor acti 90.00%
Improving conventional or low dose metronomic chemotherapy with targeted antiangiogenic drugs. 90.00%
Vitamin D binding protein-macrophage activating factor (DBP-maf) inhibits angiogenesis and tumor growth in mice. 90.00%
20(S)-25-methoxyl-dammarane-3beta, 12beta, 20-triol, a novel natural product for prostate cancer therapy: activity in vitro and 90.00%
Metronomic chemotherapy: changing the paradigm that more is better. 90.00%
Patient satisfaction with primary care: an observational study comparing anthroposophic and conventional care 90.00%
GROUNDING THE HUMAN BODY TO NEUTRALIZE BIO-ELECTRICAL STRESS FROM STATIC ELECTRICITY AND EMFs. 90.00%
Combining agents that target the tumor microenvironment improves the efficacy of anticancer therapy. 90.00%
Systems biology: a therapeutic target for tumor therapy. 86.67%
The emerging low-dose therapy for advanced cancers. 80.00%
Newcastle disease virus as an oncolytic agent. 80.00%
National Cancer Institute, National Institute of Health: Developmental Therapeutics Program. NSC 631570: results of the Human Ce 80.00%
Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecula 80.00%
Endogenous opioids regulate expression of experimental autoimmune encephalomyelitis: a new paradigm for the treatment of multipl 80.00%
Homeopathy in Advanced Lung Cancer - A Case Report 80.00%
Proapoptotic activity of Ukrain is based on Chelidonium majus L. alkaloids and mediated via a mitochondrial death pathway. 80.00%
Metronomic Schedule of Paclitaxel Is Effective in Hormone Receptor–Positive and Hormone Receptor–Negative Breast Cancer 80.00%
Synergistic inhibitory effect of gemcitabine and angiotensin type-1 receptor blocker, losartan, on murine pancreatic tumor growt 80.00%
Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. 80.00%
Cytochrome P-450 2C9 sensitizes human prostate tumor cells to cyclophosphamide via a bystander effect. 80.00%
Clinical impact of B-cell depletion with the anti-CD20 antibody rituximab in chronic fatigue syndrome: a preliminary case series 80.00%
Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory 80.00%
Individual Patient Data Meta-analysis of Survival and Psychosomatic Self-regulation from Published Prospective Controlled Cohort 80.00%
Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo. 80.00%
Enhanced radiation sensitivity and radiation recall dermatitis (RRD) after hypericin therapy – case report and review of literat 80.00%
Optimizing a novel regional chemotherapeutic agent against melanoma: hyperthermia-induced enhancement of temozolomide cytot..... 80.00%
Dihydroartemisinin (DHA) induces caspase-3-dependent apoptosis in human lung adenocarcinoma ASTC-a-1 cells. 80.00%
Effects of pomegranate juice on human cytochrome P450 2C9 and tolbutamide pharmacokinetics in rats. 75.00%
Removed from Pubmed because of suspiion of scientific fraud: Immunotherapy for Prostate Cancer with Gc Protein-Derived Macrophage-Activating Factor, GcMAF. 75.00%
A Phase I/IIA, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Crossover, Dose-Escalation, Safety Study of the Chemot 70.00%
Cryospray ablation (CSA) in the palliative treatment of squamous cell carcinoma of the esophagus. 70.00%
Itraconazole inhibits angiogenesis and tumor growth in non-small cell lung cancer. 70.00%
Intravenous ketamine therapy in a patient with a treatment-resistant major depression. 70.00%
High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and re 70.00%
Reversal of the glycolytic phenotype by dichloroacetate inhibits metastatic breast cancer cell growth in vitro and in vivo 70.00%
New therapeutic approach for brain tumors: Intranasal delivery of telomerase inhibitor GRN163. 70.00%
Confirmation of needle placement within the piriformis muscle of a cadaveric specimen using anatomic landmarks and fluoroscopic 70.00%
Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic bre 70.00%
Hyperthermia and Immunity. A Brief Overview 70.00%
Antiangiogenic effect of gemcitabine following metronomic administration in a pancreas cancer model. 70.00%
Controlled clinical evaluations of chlorine dioxide, chlorite and chlorate in man. 70.00%
Prospective study on warfarin and regional chemotherapy in patients with pancreatic carcinoma. 70.00%
Radiosurgery for spinal malignant tumors. 70.00%
Multiple cycles of intermittent chemotherapy in metastatic androgen-independent prostate cancer. 70.00%
Metronomic therapy with cyclophosphamide induces rat lymphoma and sarcoma regression, and is devoid of toxicity. 70.00%
Meta-analysis of the Related Nutritional Supplements Dimethyl Sulfoxide and Methylsulfonylmethane in the Treatment of Osteoarthr 70.00%
Circulating tumor cells in gastrointestinal malignancies: current techniques and clinical implications. 70.00%
Randomized phase II clinical trial of chemo-immunotherapy in advanced nonsmall cell lung cancer. 70.00%
Suppression of angiogenesis, tumor growth, and wound healing by resveratrol, a natural compound in red wine and grapes 70.00%
Phase II Trial of Curcumin in Patients with Advanced Pancreatic Cancer 70.00%
Focal therapy for prostate cancer: revolution or evolution? 60.00%
A phase II clinical trial of sorafenib in androgen-independent prostate cancer. 60.00%
Vitamin C: intravenous use by complementary and alternative medicine practitioners and adverse effects. 60.00%
Is there a role for herbal medicine in the treatment of pancreatic cancer?. Highlights from the "44th ASCO Annual Meeting". 60.00%
Experimental therapy of hepatoma with artemisinin and its derivatives: in vitro and in vivo activity, chemosensitization, and m 60.00%
The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary stu 60.00%
Immunostimulatory effects of low-dose cyclophosphamide are controlled by inducible nitric oxide synthase. 60.00%
N-Acetylcysteine: Multiple Clinical Applications 60.00%
Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer with metronomic UFT + CP 60.00%
Fruit and berries--interactions with drugs 60.00%
Is there a standard of care for the management of advanced pancreatic cancer?. Highlights from the Gastrointestinal Cancers Symp 60.00%
Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis. 60.00%
Synergistic antitumor effect of dichloroacetate in combination with 5-fluorouracil in colorectal cancer. 60.00%
A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung 50.00%
Role of everolimus in the treatment of renal cell carcinoma. 50.00%
Lessons learned in the development of targeted therapy for malignant gliomas 50.00%
Die Rolle von Boswellia-Säuren in der Therapie maligner Gliome: Methodische Mängel 50.00%
Phase II clinical trial results involving treatment with low-dose daily oral cyclophosphamide, weekly vinblastine, and rofe 50.00%
Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme. 50.00%
Inhibition of c-Met as a therapeutic strategy for esophageal adenocarcinoma. 50.00%
Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib. 50.00%
A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients. 50.00%
Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. 50.00%
Novel anti-angiogenic therapies for malignant gliomas. 50.00%
Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. 40.00%
Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Onco 40.00%
Improvement of cyclophosphamide activation by CYP2B6 mutants: from in silico to ex vivo. 40.00%
Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients .... 40.00%
One week on/one week off: A novel active regimen of temozolomide for recurrent glioblastoma 40.00%
Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. 30.00%
Mistletoe as a treatment for cancer. Has no proved benefit, and can cause harm 20.00%
Mitaplatin, a potent fusion of cisplatin and the orphan drug dichloroacetate. 0.00%
Dentists, dental nurses, and brain tumours 0.00%